COMPARISON OF MITOCHONDRIAL MORPHOLOGY, MITOCHONDRIAL-DNA CONTENT, AND CELL VIABILITY IN CULTURED-CELLS TREATED WITH 3 ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS DEOXYNUCLEOSIDES

被引:123
作者
MEDINA, DJ
TSAI, CH
HSIUNG, GD
CHENG, YC
机构
[1] YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06520
[2] YALE UNIV,SCH MED,DEPT LAB MED,NEW HAVEN,CT 06520
[3] VET AFFAIRS MED CTR,VIROL LAB,W HAVEN,CT 06516
关键词
D O I
10.1128/AAC.38.8.1824
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The toxic effects of various concentrations of 2',3'-dideoxycytidine (ddC), 2',3'-dideoxy-2',3'-didehydrothymidine (D4T), and 2',3'-dideoxyinosine (ddI) on CEM cells after 4 days of culture were assessed by measuring cell viability, mitochondrial DNA (mtDNA) content, and mitochondrial morphology. Cell viability and mtDNA content in drug-treated cultures were significantly reduced in a concentration-dependent fashion in comparison with cell viability and mtDNA content in untreated cultures. Cells in the treated cultures also showed significant changes in their mitochondrial morphologies which included distortion and reduction of the cristae and numerous vesicles. Unique features of the morphological changes were associated with each drug. The decrease in cell viability and mtDNA content and the increase in mitochondrial ultrastructural changes were directly related to the concentrations of the drugs used. The potencies of these compounds in reducing cell viability, mtDNA content, and normal mitochondria were in the order ddC > D4T > ddI. Comparison of the three assays used demonstrated that mtDNA content is a significantly more sensitive measure of drug toxicity than cell viability and mitochondrial morphology for the three compounds studied.
引用
收藏
页码:1824 / 1828
页数:5
相关论文
共 22 条
  • [1] AASLY J, 1990, EUR NEUROL, V30, P34
  • [2] ALDER G, 1982, Digestive Diseases and Sciences, V27, P993
  • [3] ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS)
    BARRESINOUSSI, F
    CHERMANN, JC
    REY, F
    NUGEYRE, MT
    CHAMARET, S
    GRUEST, J
    DAUGUET, C
    AXLERBLIN, C
    VEZINETBRUN, F
    ROUZIOUX, C
    ROZENBAUM, W
    MONTAGNIER, L
    [J]. SCIENCE, 1983, 220 (4599) : 868 - 871
  • [4] 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (D4T) IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX - A PHASE-I TRIAL
    BROWNE, MJ
    MAYER, KH
    CHAFEE, SBD
    DUDLEY, MN
    POSNER, MR
    STEINBERG, SM
    GRAHAM, KK
    GELETKO, SM
    ZINNER, SH
    DENMAN, SL
    DUNKLE, LM
    KAUL, S
    MCLAREN, C
    SKOWRON, G
    KOUTTAB, NM
    KENNEDY, TA
    WEITBERG, AB
    CURT, GA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (01) : 21 - 29
  • [5] CHEN CH, 1989, J BIOL CHEM, V264, P11934
  • [6] CHEN CH, 1991, MOL PHARMACOL, V39, P625
  • [7] MITOCHONDRIAL MYOPATHY CAUSED BY LONG-TERM ZIDOVUDINE THERAPY
    DALAKAS, MC
    ILLA, I
    PEZESHKPOUR, GH
    LAUKAITIS, JP
    COHEN, B
    GRIFFIN, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (16) : 1098 - 1105
  • [8] REVERSIBLE AXONAL NEUROPATHY FROM THE TREATMENT OF AIDS AND RELATED DISORDERS WITH 2',3'-DIDEOXYCYTIDINE (DDC)
    DUBINSKY, RM
    YARCHOAN, R
    DALAKAS, M
    BRODER, S
    [J]. MUSCLE & NERVE, 1989, 12 (10) : 856 - 860
  • [9] DIDANOSINE - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC POTENTIAL IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    FAULDS, D
    BROGDEN, RN
    [J]. DRUGS, 1992, 44 (01) : 94 - 116
  • [10] FREQUENT DETECTION AND ISOLATION OF CYTOPATHIC RETROVIRUSES (HTLV-III) FROM PATIENTS WITH AIDS AND AT RISK FOR AIDS
    GALLO, RC
    SALAHUDDIN, SZ
    POPOVIC, M
    SHEARER, GM
    KAPLAN, M
    HAYNES, BF
    PALKER, TJ
    REDFIELD, R
    OLESKE, J
    SAFAI, B
    WHITE, G
    FOSTER, P
    MARKHAM, PD
    [J]. SCIENCE, 1984, 224 (4648) : 500 - 503